Brainomix Validates e-Lung Technology for Pulmonary Fibrosis

Brainomix has presented new studies validating its e-Lung technology for identifying progressive pulmonary fibrosis, in collaboration with Boehringer Ingelheim.

Brainomix has presented new studies validating its e-Lung technology for identifying progressive pulmonary fibrosis, announced in a press release. The studies were showcased at the American Thoracic Society (ATS) Conference in San Francisco, highlighting the technology's accuracy and sensitivity.

The validation comes from a collaboration with Boehringer Ingelheim, utilizing data from the INBUILD clinical trial. This partnership allowed Brainomix to conduct the first quantitative CT analysis, confirming e-Lung's reliability in identifying patients at risk of progressive pulmonary fibrosis.

The Brainomix 360 e-Lung software, which quantifies CT biomarkers in interstitial lung disease patients, has recently expanded its FDA clearance. This advancement is expected to enhance patient care by enabling clinicians to track disease progression more effectively and make timely treatment decisions.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish like Life AI Weekly.

Also, consider following us on social media:

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more